Treatment Information

Back

Kidney (Renal) Cancer treatment details. Biologic therapy.

Royal Marsden Hospital, London, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:London
Treatments:Biologic therapyHospital:Royal Marsden Hospital
Drugs:Journal:Link
Date:Feb 2006

Description:

Patients: This phase II study involved 60 patients with metastatic renal cell carcinoma (RCC).

Treatment: Patients were randomized to receive thalidomide (29 patients) or medroxyprogesterone (31 patients). Thalidomide is thought to inhibit angiogenesis (the growth of new blood vessels). In the thalidomide group, 10 patients were male and 10 were female and the median age was 59.

Toxicity: Grade 4 thromboembolism and grade 3 fatigue and paresthesia were reported.

Results: This study concluded that thalidomide is not a better therapeutic than medroxyprogesterone based on the results presented. The median survival in the thalidomide arm was 8.2 months.

Correspondence: Tim Eisen, PhD, FRCP





Back